Blueblood Ventures Limited Schedules Q2 FY27 Results Board Meeting

Blueblood Ventures Limited has scheduled a November 13, 2026 board meeting to consider unaudited standalone results for Q2 and the half year ended September 30, 2026, following FY26 total revenue of ₹110.64 lakh and net profit of ₹3.26 lakh.

What will Blueblood Ventures consider at its November 13 meeting?

Blueblood Ventures will consider and approve unaudited standalone financial results for the second quarter and half year ended September 30, 2026. The meeting agenda was disclosed as a board meeting for half-yearly results, making the forthcoming filing the company’s first reported financial update for FY27.

The disclosure identifies standalone results rather than consolidated results. The board’s consideration is expected to cover the financial performance for the July-September quarter as well as the April-September half year. The available meeting information does not state any additional agenda item, business proposal, capital-raising plan, or dividend decision.

A tabular meeting record included in the available information lists November 12, 2026 as a board-meeting date announced on November 1. However, the primary board-meeting intimation identifies November 13, 2026 for considering the September 2026 results. Investors tracking the event should rely on the company’s final exchange filing for the confirmed meeting outcome and results-release date.

How did Blueblood Ventures perform in FY26?

Blueblood Ventures reported FY26 total revenue of ₹110.64 lakh, compared with ₹80.08 lakh in FY25, while net profit rose to ₹3.26 lakh from ₹0.59 lakh. The annual audited standalone financial results were approved by the board on May 27, 2026.

Revenue from operations increased to ₹79.18 lakh in FY26 from ₹50.02 lakh a year earlier. Total expenses also rose, reaching ₹106.36 lakh against ₹79.27 lakh in FY25. Profit before tax stood at ₹4.27 lakh, compared with ₹0.81 lakh in the prior financial year, and earnings per share improved to ₹0.11 from ₹0.02.

The FY26 profit increase was supported by higher revenue and improved other income, according to the reported annual-results information. These figures provide the immediate financial base against which the Q2 and H1 FY27 release will be assessed, particularly the movement in operating revenue, expenses, and profitability.

What did the earlier half-year results show?

Blueblood Ventures’ revised H1 FY26 results showed total revenue of ₹110.40 lakh and net profit of ₹16.98 lakh for the half year ended September 30, 2025. The results were revised and submitted to BSE on December 18, 2025, after the company corrected the bifurcation of trade payables in its earlier filing.

For that period, revenue from operations was ₹100.79 lakh, compared with ₹32.08 lakh in H1 FY25. Other income was ₹9.61 lakh, while total expenses were ₹93.41 lakh. Basic and diluted earnings per share were ₹0.57, compared with ₹0.03 in the corresponding previous-year half.

The auditor, KRA & Associates, issued an unmodified opinion on the revised financial results. The audit material also highlighted certain matters, including ₹756.00 lakh of zero optional convertible debentures held as non-current investments and ₹6,188.55 lakh of long-term loans and advances for which confirmations were pending. Management considered the loans and advances recoverable, while it was working to recover 247 debentures that had been transferred to another party.

Why does the Q2 FY27 filing matter to investors?

The Q2 FY27 filing matters because it will provide an updated view of Blueblood Ventures’ revenue, costs, profit and balance-sheet disclosures after the FY26 annual results and the earlier revised half-year filing. It will also allow investors to compare the new September-period performance with the reported H1 FY26 figures.

The company’s shares remain suspended on BSE following regulatory non-compliance issues dating back to 2022, according to the available information. As a result, the board meeting does not provide an immediate listed-market price signal through regular exchange trading. Nevertheless, the financial disclosure remains relevant for existing shareholders and other stakeholders monitoring compliance and corporate reporting.

The results will be particularly important for assessing whether operating revenue remains a key contributor to total revenue and whether the expense base changes materially. Investors can also review any updated disclosures relating to investments, loans and advances, since these items were specifically highlighted in the prior half-year audit material.

What should investors monitor when the results are released?

Investors should monitor the reported standalone revenue from operations, total revenue, expenses, profit before tax, net profit and earnings per share for both Q2 FY27 and H1 FY27. A comparison with the September 2025 period can show how the company’s financial performance has changed year on year.

They should also review the auditor’s report, notes to accounts, and any statement on the matters flagged in the revised H1 FY26 filing. Updates on the ₹756.00 lakh zero optional convertible debentures, including recovery efforts involving 247 debentures, and on confirmations for ₹6,188.55 lakh of loans and advances would be relevant disclosures if provided.

The meeting follows Blueblood Ventures’ 19th annual general meeting on September 30, 2026, where the company adopted standalone audited financial statements for the year ended March 31, 2026. The November board meeting is therefore the next disclosed financial-reporting event after the annual accounts were adopted.

Conclusion

Blueblood Ventures’ November 13 board meeting is focused on approving unaudited standalone Q2 and H1 FY27 results for the period ended September 30, 2026. The update follows a FY26 performance in which total revenue rose to ₹110.64 lakh and net profit increased to ₹3.26 lakh, while earlier half-year disclosures required a revision to trade-payables classification.

The next item to watch is the final board outcome and the financial-results filing, including the confirmed meeting date, period-on-period operating performance, auditor observations, and any updates on the investments and loan confirmations previously highlighted in the company’s disclosures.